Table 5.
This table summarizes the exposure to Hg from Thimerosal-preserved HepB vaccines among the cases with a premature puberty diagnosis, compared to control subjects, with a reduced length of follow-up 1, within the VSD database.
| Group Examined | Number of Cases Diagnosed with Premature Puberty (%) | Number of Controls without a Premature Puberty Diagnosis (%) | Odds Ratio (95% CI) | p-Value |
|---|---|---|---|---|
| Group I | ||||
| 12.5 µg Hg within 1st month | 255 (52.47) | 55,606 (44.79) | ||
| 1.361 (1.138–1.626) | <0.001 | |||
| 0 µg Hg within 1st month | 231 (47.53) | 68,539 (55.21) | ||
| Group II | ||||
| 25 µg Hg within first 2 months | 254 (52.59) | 55,615 (45.30) | ||
| 1.34 (1.120–1.602) | <0.01 | |||
| 0 µg Hg within first 2 months | 229 (47.41) | 67,163 (54.70) | ||
| Group III | ||||
| 37.5 µg Hg within first 6 months | 56 (81.16) | 11,786 (72.65) | ||
| 1.622 (0.886–2.969) | >0.10 | |||
| 0 µg Hg within first 6 months | 13 (18.84) | 4438 (27.35) |
1 The controls were continuously enrolled from their date of birth for a minimum of 2.94 years (mean age of the initial premature puberty diagnosis. Hg = mercury, µg = microgram.